Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Oncology Consultants

Houston, Texas 77030, United StatesNot linked to an institution yet

21running trials
9closed trials

The trials here

What the 30 trials at this site are about, from their registry records.

Conditions: Lung cancer10 trials
Gastric and oesophageal cancer6 trials
Colorectal cancer5 trials
Head and neck cancer5 trials
Metastatic breast cancer4 trials
Ovarian cancer4 trials
Pancreatic cancer4 trials
Prostate cancer4 trials
Endometrial cancer3 trials
Melanoma3 trials
Sarcoma3 trials
Bladder cancer2 trials
and 11 more
Phase: Phase 110 trials
Phase 1/26 trials
Phase 35 trials
Phase 24 trials
Phase 2/31 trial
Status: Recruiting12 trials
Active, not recruiting8 trials
Completed6 trials
Terminated2 trials
Not yet recruiting1 trial
Withdrawn1 trial
Lead sponsor: Amgen2 trials
Aadi Bioscience, Inc.1 trial
All4Cure1 trial
Artios Pharma Ltd1 trial
Astellas Pharma Global Development, Inc.1 trial
and 24 more

Running trials

Recruiting
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498· Phase 2· Kyntra Bio· Source
Contact: Julio Peguero
Recruiting
An External Control Arm Study in Non-Small Cell Lung Cancer
NCT07174388· N-Power Medicine· Source
Contact: Research Office
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
NCT07176650· Phase 1· Shanghai Henlius Biotech· Source
Contact: Henlius
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473· Phase 1· Phrontline Biopharma· Source
Contact: Julio Peguero, Md
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Recruiting
SLV-154 Treatment of Advanced Cancers
NCT06771219· Phase 1· Solve Therapeutics· Source
Contact: Julio Peguero, MD
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864· BostonGene· Source
Contact: Laura Guerra
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898· Phase 1· SystImmune Inc.· Source
Contact: Laura Guerra
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Contact: Clinical Trials Office
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363· Phase 1· Carna Biosciences, Inc.· Source
Contact: Laura Guerra, RN, CCRC
Recruiting
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT05735080· Phase 1/2· Incyclix Bio· Source
Contact: Site PI
Active, not recruiting
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
NCT05673083· All4Cure· Source
Recruiting
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
NCT05651932· Phase 1· K36 Therapeutics, Inc.· Source
Contact: Dr. Julio A. Peguero, MD
Active, not recruiting
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· Phase 3· Celcuity Inc· Source
Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· Phase 3· Gilead Sciences· Source
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132· Phase 1/2· Synthekine· Source
Active, not recruiting
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487· Phase 1/2· Nimbus Saturn, Inc.· Source
Active, not recruiting
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847· Phase 1· Incyte Corporation· Source
Active, not recruiting
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526· Phase 1/2· OncoC4, Inc.· Source
Active, not recruiting
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883· Phase 1· Amgen· Source
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835· Phase 1/2· Genmab· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer5 recruiting
Gastric and oesophageal cancer3 recruiting
Head and neck cancer2 recruiting
Liver and biliary tract cancer2 recruiting
Ovarian cancer2 recruiting
Prostate cancer2 recruiting
Bladder cancer1 recruiting
Cervical cancer1 recruiting
Childhood cancers1 recruiting
Chronic lymphocytic leukaemia1 recruiting
Colorectal cancer1 recruiting
Endometrial cancer1 recruiting
Follicular lymphoma1 recruiting
Mantle cell lymphoma1 recruiting
Melanoma1 recruiting
Metastatic breast cancer1 recruiting
Multiple myeloma1 recruiting
Sarcoma1 recruiting

Closed trials

Terminated
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
NCT05169437· Phase 2· Tempus AI· Source
Completed
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
NCT05103358· Phase 2· Aadi Bioscience, Inc.· Source
Completed
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC
NCT04811027· Phase 2· Immutep S.A.S.· Source
Recruiting
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114· Phase 1· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Terminated
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
NCT04795713· Phase 1· Molecular Templates, Inc.· Source
Recruiting
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068· Phase 1/2· Artios Pharma Ltd· Source
Contact: Sarah Cannon Development Innovations
Completed
Prevention of Colorectal Cancer Through Multiomics Blood Testing
NCT04369053· Freenome Holdings Inc.· Source
Completed
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· Phase 3· Ipsen· Source
Completed
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
NCT04082364· Phase 2/3· MacroGenics· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error